Tenderwize
Zurück zur Suche

Open House Discount Contracts for Ranibizumab (Vial)

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ranibizumab, als Durchstechflasche, ATC S01LA04

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

25 / 100

Risikofaktoren

The buyer reserves the right to replace open-house contracts with exclusive contracts from EU tenders, which would auto...

As an open-house model, there is no guaranteed purchase volume or spend; contracts are purely discount agreements.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of non-exclusive discount contracts for the active substance Ranibizumab (ATC S01LA04) as a vial.
  • Contracts are open to all interested pharmaceutical companies meeting the eligibility criteria.
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount contracts (Rabattverträge) for the pharmaceutical product Ranibizumab (ATC S01LA04) as a vial, offered by AOK Rheinland-Pfalz/Saarland. The contract period is from 01.06.2025 to 31.05.2027, with the possibility to join at any month start. The first submission deadline for the initial contract start is 30.04.2025. No estimated value is provided. This is not a classic procurement but a voluntary transparency publication.

Risiken

The buyer reserves the right to replace open-house contracts with exclusive contracts from EU tenders, which would auto...

As an open-house model, there is no guaranteed purchase volume or spend; contracts are purely discount agreements.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Pharmaceutical company must offer authorized and marketable drugs in Germany.

Administrative

  • Drugs must be listed in the Lauer-Taxe as marketable; otherwise, evidence from AMIce database or other documentation is required.
  • Submission of signed contract documents by specified deadlines.

Anforderungen können unvollständig sein.

Auftraggeber

Lose (1)

LOT-0001

Open House Discount Contracts for Ranibizumab (Vial)

Non-exclusive discount contracts for Ranibizumab (ATC S01LA04) as a vial. Maximum contract duration 24 months from 01.06.2025 to 31.05.2027. First contract conclusion possible on 01.06.2025. All contracts end at the latest 24 months after the earliest start date. Open to all interested pharmaceutical companies offering authorized and marketable drugs in Germany.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Expired Apr 30, 2025

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
236800-2025

Dokumente (1)

Ähnliche Ausschreibungen